Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Scott Tykodi, MD, PhD, Discusses Gene Expression Analysis and Mutational Profiling in KEYNOTE-427 Trial for RCC

Dr Tykodi, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, shares data analyses of cohort A from the KEYNOTE-427 trial on first-line pembrolizumab for clear cell renal cell carcinoma, presented in two abstracts at the virtual 2020 ASCO Annual Meeting.

Advertisement

Advertisement

Advertisement

Advertisement